Relay Therapeutics Inc (RLAY) - News Archive

In the evolving landscape of oncology therapies, Relay Therapeutics has announced notable updates regarding its investigational drug, RLY-2608, in combination with fulvestrant for the treatment of patients with PI3K-mut...

In a pivotal moment for precision oncology, Relay Therapeutics Inc. (NASDAQ: RLAY) has announced encouraging interim data from its ongoing trial of RLY-2608, a targeted therapy designed for patients with advanced solid...

: Relay Therapeutics has announced a webcast slated for September 9, 2024, during which the company will share crucial data regarding its investigational drug RLY-2608. This article examines the significance of this upc...

Relay Therapeutics and Pfizer Collaborate on Groundbreaking Clinical Trial for PI3K-Mutated HR+/HER2- Metastatic Breast CancerIn an exciting development in the fight against metastatic breast cancer, Relay Therapeutics...